About this Research Topic
In 2014 and 2015 a group of Canadian oncologists contributed to a Frontiers in Oncology Research Topic with a series of review articles about the different treatments of metastatic non-small cell lung cancer (NSCLC).
The knowledge about the treatments with different targeted agents in metastatic NSCLC is growing rapidly, both in the area of EGFR TKIs and ALK inhibitors as single agents and their combinations with other treatments, such as chemotherapy, antiangiogenic agents, immunotherapy or new targeted agents. Proper sequencing of different treatments and trying to deal with the development of treatment resistance to these agents are challenging, but progress is being achieved.
New data on immunotherapy are very exciting and encouraging, as these treatments have long lasting responses and show a significant impact on survival in this group of patients. New tumor targets are being investigated in clinical trials and these trials are going to be described in this Research Topic.
We believe that these exciting new data are already changing our practice and warrant an updated report and change of the treatments' algorithms.
The first edition of this collection is available here: The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.